IgA nephropathy is the most common primary glomerulonephritis in China, more than 50% of primary nephritis is IgA nephropathy, the vast majority of IgA nephropathy presents slow progression of kidney function, on average 1-2% of patients each year will develop to end-stage renal failure, is the most common cause of uremia in young people. The clinical presentation of IgA nephropathy is varied, and many patients have no obvious symptoms and are not aware of any problems. It may only be suspected during routine screening or research for other diseases. The main types of IgA nephropathy include the following, in order of incidence: 1. recurrent hematuria (30-40%): occurs hours to 1-2 days after an upper respiratory tract infection (gastrointestinal or urinary tract infection), mostly without concomitant symptoms, a few have urinary discomfort and are diagnosed as acute cystitis; 2. insidious nephritis (20-30%): microscopic hematuria, 25% 3. chronic nephritis: microscopic hematuria with or without proteinuria (+-++), often with hypertension; 4. massive proteinuria or nephrotic syndrome: nephrotic syndrome with or without microscopic hematuria, mostly with hypertension. II. Treatment: Since IgAN is a group of diseases consisting of various clinical manifestations and different pathological changes, the analysis of evidence-based medical studies conducted with IgAN as the overall concept has so far failed to yield clear guiding therapeutic opinions. Existing studies and analyses show that: massive proteinuria, hypertension, renal impairment and degree of pathological damage are the influencing factors that determine the prognosis of IgAN patients. Since the control of hypertension is not very different from the treatment of other renal diseases, several other influencing factors are used as entry points to analyze and organize the evidence-based medical treatment recommendations for IgAN. 1, normal renal function: urine protein less than 1g, except for long-term follow-up, patients with urine protein >0.5g can be given ACEI class treatment. Urine protein 1-3.5g, give 6 months hormone therapy, can reduce urine protein to stabilize renal function. Urine protein >3.5g, with renal syndrome as the manifestation and light pathological type, given 4-6 months of hormone therapy. 2, renal insufficiency: Scr133-250μmol/ l, give hormone and cytotoxic drugs, prednisone 40mg/d, and then reduce to 10 mg/d in two years, CTX1.5mg/kg/d treatment for 3 months and then give AZA1.5mg/kg/d for at least 2 years, can be given at the same time Pansentin 75mg/d or low dose warfarin treatment, can significantly protect renal function. 3.Other : ACEI or ARB is preferred for blood pressure control, and removal of tonsils in patients with recurrent tonsillitis can help reduce symptoms.